Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Shares Outstanding (Weighted Average) (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $171.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 5.6% to $171.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $171.7 million, a 5.6% increase, with the full-year FY2024 number at $164.5 million, up 19.73% from a year prior.
  • Shares Outstanding (Weighted Average) was $171.7 million for Q3 2025 at Denali Therapeutics, roughly flat from $171.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $171.7 million in Q3 2025 to a low of $120.9 million in Q1 2021.
  • A 5-year average of $140.9 million and a median of $136.8 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 1.42% in 2022, then increased 19.73% in 2024.
  • Denali Therapeutics' Shares Outstanding (Weighted Average) stood at $121.5 million in 2021, then rose by 3.3% to $125.5 million in 2022, then grew by 9.43% to $137.4 million in 2023, then rose by 19.73% to $164.5 million in 2024, then grew by 4.39% to $171.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Shares Outstanding (Weighted Average) are $171.7 million (Q3 2025), $171.4 million (Q2 2025), and $171.2 million (Q1 2025).